218 related articles for article (PubMed ID: 10537309)
1. Structure-function studies of the BTB/POZ transcriptional repression domain from the promyelocytic leukemia zinc finger oncoprotein.
Li X; Peng H; Schultz DC; Lopez-Guisa JM; Rauscher FJ; Marmorstein R
Cancer Res; 1999 Oct; 59(20):5275-82. PubMed ID: 10537309
[TBL] [Abstract][Full Text] [Related]
2. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.
Puccetti E; Zheng X; Brambilla D; Seshire A; Beissert T; Boehrer S; Nürnberger H; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Cancer Res; 2005 Jul; 65(14):6080-8. PubMed ID: 16024608
[TBL] [Abstract][Full Text] [Related]
3. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions.
Melnick A; Ahmad KF; Arai S; Polinger A; Ball H; Borden KL; Carlile GW; Prive GG; Licht JD
Mol Cell Biol; 2000 Sep; 20(17):6550-67. PubMed ID: 10938130
[TBL] [Abstract][Full Text] [Related]
4. Overexpression, purification, characterization, and crystallization of the BTB/POZ domain from the PLZF oncoprotein.
Li X; Lopez-Guisa JM; Ninan N; Weiner EJ; Rauscher FJ; Marmorstein R
J Biol Chem; 1997 Oct; 272(43):27324-9. PubMed ID: 9341182
[TBL] [Abstract][Full Text] [Related]
5. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
6. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene.
Davies JM; Hawe N; Kabarowski J; Huang QH; Zhu J; Brand NJ; Leprince D; Dhordain P; Cook M; Morriss-Kay G; Zelent A
Oncogene; 1999 Jan; 18(2):365-75. PubMed ID: 9927193
[TBL] [Abstract][Full Text] [Related]
7. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
[TBL] [Abstract][Full Text] [Related]
8. A beta-sheet interaction interface directs the tetramerisation of the Miz-1 POZ domain.
Stead MA; Trinh CH; Garnett JA; Carr SB; Baron AJ; Edwards TA; Wright SC
J Mol Biol; 2007 Nov; 373(4):820-6. PubMed ID: 17880999
[TBL] [Abstract][Full Text] [Related]
9. The BTB/POZ domain of the regulatory proteins Bric à brac 1 (BAB1) and Bric à brac 2 (BAB2) interacts with the novel Drosophila TAF(II) factor BIP2/dTAF(II)155.
Pointud JC; Larsson J; Dastugue B; Couderc JL
Dev Biol; 2001 Sep; 237(2):368-80. PubMed ID: 11543621
[TBL] [Abstract][Full Text] [Related]
10. Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions.
Peng H; Begg GE; Schultz DC; Friedman JR; Jensen DE; Speicher DW; Rauscher FJ
J Mol Biol; 2000 Feb; 295(5):1139-62. PubMed ID: 10653693
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional repression by the proto-oncogene BCL-6.
Seyfert VL; Allman D; He Y; Staudt LM
Oncogene; 1996 Jun; 12(11):2331-42. PubMed ID: 8649773
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the BTB domain from PLZF.
Ahmad KF; Engel CK; Privé GG
Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12123-8. PubMed ID: 9770450
[TBL] [Abstract][Full Text] [Related]
13. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein.
David G; Alland L; Hong SH; Wong CW; DePinho RA; Dejean A
Oncogene; 1998 May; 16(19):2549-56. PubMed ID: 9627120
[TBL] [Abstract][Full Text] [Related]
15. A L225A substitution in the human tumour suppressor HIC1 abolishes its interaction with the corepressor CtBP.
Stankovic-Valentin N; Verger A; Deltour-Balerdi S; Quinlan KG; Crossley M; Leprince D
FEBS J; 2006 Jul; 273(13):2879-90. PubMed ID: 16762039
[TBL] [Abstract][Full Text] [Related]
16. Molecular cloning and characterization of a novel human BTBD8 gene containing double BTB/POZ domains.
Xu J; He T; Wang L; Wu Q; Zhao E; Wu M; Dou T; Ji C; Gu S; Yin K; Xie Y; Mao Y
Int J Mol Med; 2004 Jan; 13(1):193-7. PubMed ID: 14654994
[TBL] [Abstract][Full Text] [Related]
17. Myoneurin, a novel member of the BTB/POZ-zinc finger family highly expressed in human muscle.
Alliel PM; Seddiqi N; Goudou D; Cifuentes-Diaz C; Romero N; Velasco E; Rieger F; Périn JP
Biochem Biophys Res Commun; 2000 Jun; 273(1):385-91. PubMed ID: 10873615
[TBL] [Abstract][Full Text] [Related]
18. HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF.
Chauchereau A; Mathieu M; de Saintignon J; Ferreira R; Pritchard LL; Mishal Z; Dejean A; Harel-Bellan A
Oncogene; 2004 Nov; 23(54):8777-84. PubMed ID: 15467736
[TBL] [Abstract][Full Text] [Related]
19. The BTB/POZ domain: a new protein-protein interaction motif common to DNA- and actin-binding proteins.
Albagli O; Dhordain P; Deweindt C; Lecocq G; Leprince D
Cell Growth Differ; 1995 Sep; 6(9):1193-8. PubMed ID: 8519696
[TBL] [Abstract][Full Text] [Related]
20. The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo.
Dhordain P; Albagli O; Ansieau S; Koken MH; Deweindt C; Quief S; Lantoine D; Leutz A; Kerckaert JP; Leprince D
Oncogene; 1995 Dec; 11(12):2689-97. PubMed ID: 8545127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
